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Abstract
Background: The microRNA-based gene-silencing machinery has been recognized as a promising approach to
control viral replication and used for improving safety for the live attenuated virus vaccines. The effective host
microRNA response elements (MREs) have been incorporated into a virus sequence mainly based on the
experimental trials for identifying both microRNA binding sites and effective mutations. The design of MREs for
viral genomes or with multiple host microRNAs of interest, then, will be time and cost consuming.
Results: In this paper, we introduced a computational flow that could be used to design MREs of human
microRNAs within Influenza A H1N1 virus gene segments. The main steps of the flow includes locating possible
binding sites; MREs, of human microRNAs within the viral sequences using a miRNA target prediction tool
(miranda), performing various mutations among mismatched binding positions, calculating the binding energy,
score, identity, and the effects of changed physical properties of amino acids according to the changed bases in
RNA level, and prioritizing the mutated binding sites. The top ranked MREs of human microRNA hsa-miR-93 is
consistent with previous literature while other results waited to be experimentally verified. To make the
computational flow easily accessible by virologists, we also developed MicroLive, a web server version of the MRE
design flow together with the database of miranda-predicted MREs within gene sequences of seven RNA viruses
including Influenza A, dengue, hepatitis C, measles, mumps, poliovirus, and rabies. Users may design MREs of
specific human microRNAs for their input viral sequences using MRE design tool or optimize the miranda-predicted
MREs of seven viruses available on the system. Also, users could design varied number of MREs for multiple human
microRNAs to modulate the degree of live vaccine attenuation and reduce the likelihood of escape mutants.
Conclusions: The computational design of MREs helps reduce time and cost for experimental trials. While the flow
was demonstrated using human microRNAs and Influenza A H1N1 virus, it could be flexibly applied to other hosts
(e.g., animals) and viruses of interest for constructing host-specific live attenuated vaccines. Also, it could be
deployed for engineering tissue-specific oncolytic viruses in cancer virotherapeutics. The MicroLive web server is
freely accessible at http://www.biotec.or.th/isl/microlive.
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Background
MicroRNAs (miRNAs) are a class of naturally occurring,
single-stranded non-coding RNA molecules approximately
21-25 nucleotides in length. It has been shown that miR-
NAs are, to some extent, complementary to messenger
RNA (mRNA) molecules in most, if not all, eukaryotic
cells and that their main function is to inhibit gene expres-
sion via a number of mechanisms, such as direct mRNA
cleavage, translational repression, and deadenylation [1].
In general, miRNAs function by guiding the RNA-induced
silencing complex (RISC) to their target sites, resulting in
inhibition of mRNA translation followed by deadenylation
and rapid degradation of mRNA [2].
The anti-viral role of cellular miRNA was best estab-
lished by the discovery that an endogenous miRNA,
termed miR-32, could suppress the replication of primate
foamy virus type-1 (PFV-1) in human cells [3]. During
viral replication, miR-32 could bind viral mRNA, with
imperfect complementarity, leading to suppression of viral
protein synthesis and viral replication. Since then, many
more cellular miRNAs have been discovered and its anti-
viral effect identified. For instance, a cellular miR-29a in
T cells was found to strongly inhibit replication of HIV-1
via a highly conserved target site in the viral genome [4].
Host-encoded miR-101 was found to substantially sup-
press herpes simplex virus-1 (HSV-1) replication by target-
ing the 3’ UTR of mitochondrial ATP synthase subunit
beta [5]. It also has been shown that cellular miR-323,
miR-491, and miR-654 could inhibit replication of the
H1N1 influenza A virus through binding to the PB1 gene
[6]. Cellular miRNAs miR-24 and miR-93 were reported
to target viral large protein (L protein) and phosphopro-
tein (P protein) genes and their decreased expression
increased vesicular stomatitis virus (VSV) replication [7].
Taken together, these findings strongly suggest that bind-
ing cellular miRNAs to its target sequences in the viral
mRNA could be another mechanism by which invading
viruses could be counteracted by the host.
Mounting studies have demonstrated that cellular
miRNA-mediated anti-viral property is a promising
approach for development of attenuated viruses as live
vaccines. When the poliovirus was engineered to harbor
endogenous miRNA-complementary target sequences, it
became highly attenuated as evinced by its poor growth in
cells expressing the corresponding miRNA. Moreover,
mice infected with these modified viruses exhibited barely
detectable sign of disease, and, importantly, they were pro-
tected against lethal challenge with a pathogenic poliovirus
[8]. Likewise, Perez and colleagues have generated a panel
of influenza viruses by incorporating non-avian miRNA
response elements (MREs) into the viral nucleoprotein;
they could generate H1N1 and H5N1 influenza viruses
that were attenuated in mice but not in eggs [9]. Recently,
dengue virus replicon was also modified to carry the
sequence target of hepatic-specific miR-122 at its 3’-UTR
and this virus growth in liver cells was highly restricted
[10].
Besides improving safety for live attenuated virus vac-
cines, the engineering of viruses with the miRNA response
elements produces potent oncolytic viruses which are tis-
sue-specifically safe. Cawood and colleges engineered an
adenovirus 5 (Ad5) with the inserted binding sites of hepa-
tocyte-specific miR-122 within the 3’-UTR of E1A tran-
scription cassette which resulted in liver-safe oncolytic
virus with full activity in cancer cells [11]. Herpes Simplex
Virus-1 (HSV-1) was engineered to incorporate the bind-
ing sites of miR-143 and miR-145 into the 3’-UTR of ICP4
gene. This significantly reduced virulence to normal tis-
sues but maintained the killing of prostate cancer cells
[12]. Edges and colleagues incorporated the complemen-
tary sequence of let-7 microRNA within Vesicular Stoma-
titis Virus (VSV), a rhabdovirus, to eliminate undesirable
replication and toxicity in normal cells but still grow in
cancer cells [13]. Kelly and colleagues inserted miR-125
target sequences into the 3’-UTR of the polymerase (L)
gene of the Vesicular Stomatitis Virus (VSV) to reduce the
neurotoxicity [14]. Coxsackievirus A21 (CVA21), a picor-
navirus, was also engineered with target elements of the
muscle-specific miR-1, miR-133a, and miR-206 to retain
the oncolytic activity but protect myositis [15].
These studies clearly indicate that, with the advent of
reverse genetics technology, it is possible to manipulate
the infectious clones of virus of interest by incorporating
the miRNA target sequences of choice into the viral gen-
ome and construct recombinant viruses for the develop-
ment of live attenuated vaccines or tissue-specific
oncolytic viruses for cancer virotherapy.
The inserted positions of MREs into a viral genome could
be varied from 3’-UTR to open reading frames (ORFs) with
different complexities (e.g., the highly-structured RNA, the
possibly available RNA pseudoknots, the cyclization/con-
served sequences and stem-loop regions in 3’-UTR, or
the effects of physical properties according to mutated
bases in RNA level of the ORFs). Without computer-aided
tools, the proper MRE positions and mutations would be
mainly identified by experimental trials. To ease the design
of MREs and to reduce time for wet-lab experiments, here,
we proposed a computational flow and a web server for
designing MREs of human miRNAs that could be incorpo-
rated into the open reading frames (ORFs) of a viral gen-
ome with efficacy, and having no or least effects on physical
properties of amino acids due to mutated bases in RNA
level. The results of the entire computational flow was
demonstrated via the designed MREs within gene segments
of Influenza A H1N1 virus for a set of human miRNAs.
The developed web server consists of two parts: 1) the
MRE design tool that implemented the computational flow
with web interfaces allowing users to customize binding
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parameters and mutate binding positions with score recal-
culations, and 2) the database of seven RNA viruses with
miranda-predicted MREs that could be further optimized
and prioritized as effective MREs for wet-lab experiments.
Materials and methods
Data compilation
To demonstrate the entire flow of MRE design, sequences
of previously reported human (Homo sapiens) miRNAs
were extracted from miRBase [16,17] release 14. The total
122 human miRNAs of interest remained after verifying
their conservation with mouse (Mus musculus) but not
chicken (Gallus domesticus) as Influenza virus was nor-
mally cultivated in eggs. The number of remaining miR-
NAs was further reduced according to their ubiquitous
expression in various tissues. The total 19 out of 122 miR-
NAs expressed in more than five tissues were extracted
from supplemental data of [18] (see Additional file 1 for
the list of these miRNAs) and selected as host miRNAs of
interest for MRE design. The Influenza RNA sequences
(influenza.cds.gz) was downloaded from ftp://ftp.ncbi.nih.
gov/genomes/INFLUENZA/ on January, 2010. Sequences
of Influenza A H1N1 virus were grouped into eight files
with 1019, 1019, 1015, 1051, 1022, 1047, 1035, and 1017
sequences according to gene segments PB2, PB1, PA, HA,
NP, NA, M, NS.
To build a database of miranda-predicted MREs, Influ-
enza A sequences of H1N1, H1N2, H2N2, and H3N2
viruses were downloaded from Influenza Virus Resource at
NCBI (http://www.ncbi.nlm.nih.gov/genomes/FLU/FLU.
html) at the end of August 2010. Other virus sequences
including dengue virus (types 1-4), hepatitis C virus (geno-
types 1-6), measles, mumps, human poliovirus (1-3), and
rabies were collected from NCBI viral genomes resource
(http://www.ncbi.nlm.nih.gov/genomes/GenomesHome.
cgi?taxid=10239) during August 31-September 3, 2010 (see
Additional file 2 for the number of compiled viral
sequences). The compiled sequences of the same gene or
gene segment of a specific virus (e.g., gene segment 5 of
Influenza A H1N1 or NS2A gene of dengue virus type 1),
were grouped together, cleaned and then aligned using
MUSCLE [19]. These alignment results were prepared as a
part of the online database for helping users choose the
predicted MREs for further optimization according to their
conserved regions over sequence population. All human
miRNAs were extracted from miRBase release 16.
Computational identification and prioritization of
host MREs
The computational flow used to design potential miRNA
response elements (MREs) consists of three main phases
as demonstrated in Figure 1. First phase, the possible bind-
ing sites (MREs) of host miRNAs on viral sequences were
predicted by miranda [20,21] (version v3.3a), an miRNA
target prediction tool, with default parameter setting and
the binding energy cutoff was less than or equal to
-15 KCal/Mol. Virologists might simply incorporate these
MREs into their input viral sequences. This however does
not guarantee the binding effectiveness. Second phase, the
miranda-predicted MREs were regenerated with all combi-
nations of mutations from the non-complementary to
complementary positions with the recalculation of binding
score and energy, the measurement of amino acid sub-
stitutions and the effects on their physical properties (e.g.,
hydrophobicity, polarity and/or charge) due to the
mutated bases in the RNA level. Third phase, the mutated
MREs would be prioritized; they will be top ranked if 1)
located on conserved open reading frames (ORFs) of the
same gene across sequence population, 2) having high
binding score and low binding energy against the host
miRNA, and 3) having small number of amino acid substi-
tutions and getting no or least effects on their physical
properties. Multiple MREs for the same miRNAs and/or
different miRNAs will be also summarized as alternative
MREs that could be deployed simultaneously to alleviate
the effects of viral mutation across the generations. All
these steps were implemented as a set of Python codes.
To make the MRE design tool publicly accessible and
usable by virologists, we also implemented the computa-
tional flow as a web server called MicroLive and a data-
base of miranda-predicted MREs, including binding sites,
binding score, binding energy, and percent identity,
resulted from first phase of the computational flow, of all
human miRNAs from miRBase release 16 within seven
RNA viruses. This database could be the starting point of
virologists to try the online MRE design tool to optimize
and prioritize the MREs.
Results and discussions
Prioritized MREs for influenza A H1N1 virus
This section demonstrates the final result generated by run-
ning the entire steps of the computational flow to find the
potential MREs for a set of human microRNAs against
eight segments of Influenza A H1N1 2009 virus (see Mate-
rials and Methods section). Nine distinct binding sites of
six human miRNAs, hsa-miR-25, hsa-miR-92a, hsa-miR-93,
hsa-miR-99b, hsa-miR-191, and hsa-miR-503 were top
ranked by the prioritization with binding energy lower than
-37 KCal/Mol and having at most two amino acid substitu-
tions without effects on physical properties (see Additional
file 3). These MREs were located within gene segments 2,
4, 5, 6, or 7 of Influenza A H1N1 virus. Among them, an
MRE of hsa-miR-93 with binding position 772-794 nt
(from the start codon) was identified within segment 5
(NP) of the Influenza A H1N1 virus and consistent with
Site 2 in [9]. Site 1 in [9] was not identified by our binding
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energy cutoff. Human miRNAs hsa-miR-99b and hsa-miR-
503 has an MRE with only single amino acid substitution
on segment 6 (NA) and segment 4 (HA), respectively. In
addition, hsa-miR-25 has multiple MREs on gene segment
2 (PB1). These prioritized MREs are considered potential
MREs for wet-lab experiments.
MRE design tool
The MRE design tool implemented the computational
flow of MRE design into a web-based application of two
main steps: I) identify the possible binding sites of a
human miRNA within input virus sequences, II) design
MREs from the binding sites of interest. In the first step,
users need to 1) select a specific human miRNA of inter-
est, 2) paste or upload a set of viral sequences of the
same gene or gene segment with the maximum file size
limited to 1MB, and 3) specify the cutoff parameters for
keeping the possible miRNA-virus binding sites. From
Example 1 (see Figure 2A), with selected human miRNA
hsa-miR-93 and two input sequences of segment 5 (NP),
gi|8486129:A/Puerto Rico/8/34(H1N1) and gi|89779327:
A/Puerto Rico/8/34(H1N1) of Influenza A virus with
minimum score and maximum energy as 80 and -15
KCal/Mol, we got 18 records of input sequences with
nine binding sites (see Figure 2B). From here, we could
filter the list of records according to a specific conserved
binding site and start the MRE design step. We selected
the binding site 772-794 in this example as it has the
highest score and lowest binding energy and is conserved
between the two input sequences. The conserved sites
could be explored through the “Alignment View” visua-
lized using Jalview [22]. Under the “Target View”, the
click on “Design MREs” button a of any sequences hav-
ing the conserved binding site will open a “Show muta-
tion” window (Figure 3). Here, users could iteratively
mutate mismatched binding positions, rerun miranda,
and explore the recalculated binding score, binding
energy, the number of changed amino acids, and the
effects on their physical properties. Users may export the
mutated sequence if required. The click on “View
sequence and detail” button b (Figure 2B) will open a
new window (Figure 4A) displaying the selected sequence
with highlighted target sites and percent of nucleotide
content whereas the click on “See other miRNAs that tar-
get the same binding site” button c will open a new win-
dow (Figure 4B) with a list of miRNAs with the same
binding site. Users could use some of these miRNAs as
alternatives for the rerun of MRE design.
Figure 1 Overall workflow for the computational identification of potential miRNA response elements (MREs).
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Database of miranda-predicted human MREs
Search utility
The MicroLive database contains the list of miranda-
predicted MREs of all human miRNAs in miRBase
release 16 within seven RNA viruses: Influenza A
(H1N1, H1N2, H2N2, and H3N2), dengue virus (types
1-4), hepatitis C virus (genotypes 1-6), measles, mumps,
poliovirus (1-3), and rabies. To search these MREs
Figure 2 The first phase of MRE design tool interface: (A) parameter setting of Example 1, and (B) results of input sequence
alignment and potential binding sites of the selected human miRNA.
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Figure 3 The second phase of MRE design tool interface: (A) interface for mutating mismatched positions, (B) the recalculated binding
score, energy, and the effects of amino acid substitutions according to mutated positions.
Figure 4 The additional information of an input sequence containing miranda-predicted MREs: (A) sequence detail with highlighted
target sites and percent of nucleotide content, (B) list of other miRNAs targeting the same site.
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within a virus, users need to select a gene or gene seg-
ment of a virus and a specific human miRNA of inter-
est, customize the binding parameters including the
minimum binding score, maximum binding energy, and
alignment length that represent the binding affinity of
the chosen miRNA on the MREs, and submit the search
request. The selected segment 5 (NP) of Influenza A
H1N1 virus in Bangkok with selected human miRNA
hsa-miR-93 and default binding parameters setting (e.g.,
minimum score, maximum energy, and alignment length
is equal to 80, -15 KCal/Mol, and 10 bp, respectively),
resulted in five distinct NP genes, each with two binding
positions. From here, users could select one of the bind-
ing positions of interest based on their conservation in
the “Alignment View,” and click on “Design MREs” but-
ton on the left of any sequences in the group for trying
the MRE design step as described in the design tool
section.
Conserved positions of miranda-predicted MREs
This section gives examples of the potential start sites of
miranda-predicted MREs within Influenza A viruses,
dengue types 1-4, and rabies according to their con-
served start binding positions of specific miRNAs within
or across gene sets.
Influenza A viruses The numbers of human miRNAs
identified with the miranda-predicted MREs on specific
viral genes or gene segments were varied (see Additional
file 4). We found two human miRNAs hsa-miR-637 and
hsa-miR-760 having MREs (with binding energy <= -30
KCal/Mol) within gene segment 5 (NP) across the four
Influenza A H1N1, H1N2, H2N2, and H3N2 viruses.
The start binding position 521 of hsa-miR-637 within
the segment was highly conserved among gene popula-
tions of H1N2, H2N2, and H3N2 viruses. Additionally,
the start binding positions 537 and 560 of hsa-miR-760
of the three viruses were also highly conserved. All
these start binding positions were specific to the corre-
sponding human miRNAs. All viruses except H1N1 also
shared MREs of another human miRNA hsa-miR-657
with highly conserved binding position 639. Specific to
Influenza A H1N1 virus, the start binding positions
1161, 65, and 1190 of hsa-miR-1538, hsa-miR-4254, and
hsa-miR-4286 were highly conserved among more than
thousand sequences of segment 5 within the population.
These positions were considered potential start positions
for the design of MREs.
Dengue viruses With the same binding energy cutoff, we
found two human miRNAs hsa-miR-370 and hsa-miR-661
having MREs within NS1 genes of all types of dengue
virus. The start binding position 771 of hsa-miR-370 was
highly conserved among gene population of types 1-3
while hsa-miR-661 had a highly conserved start binding
position 789 among gene population of all types. Both
start binding positions were specific to the corresponding
miRNAs. Besides the conserved start position 771, posi-
tions 139 of hsa-miR-1470, 141 of hsa-miR-3622a-3p, 148
of hsa-miR-485-3p, and 582 of hsa-miR-770-5p were
highly conserved among more than one thousand
sequences of NS1 genes in type 1 while position 137 was
predicted start binding position of both hsa-miR-1236 and
hsa-miR-1249. The start binding positions 304 of hsa-
miR-762 and 308 of hsa-miR-3677 were highly conserved
among more than five hundred NS1 genes in type 2 while
positions 765 of hsa-miR-637 and 773 of hsa-miR-3663-5p
were highly conserved among almost three hundred NS1
sequences in dengue type 3.
Rabies More than two hundred nucleoprotein (NP)
genes of rabies virus were predicted with highly con-
served start binding positions 122 of hsa-miR-939, 359
of hsa-miR-770-5p, and 820 of hsa-miR-2277-3p and
hsa-miR-638. Interestingly, more than one hundred of
phosphoprotein (P) genes contained two conserved posi-
tions 530 and 531 which were targeted by multiple miR-
NAs. Start position 530 was targeted by hsa-miR-3131,
hsa-miR-4298, and hsa-miR-939 while position 531 was
targeted by hsa-miR-134 and hsa-miR-3180-3p. Like-
wise, six start binding positions found conserved across
hundred of glycoprotein genes. Top three of them were
positions 87 of hsa-miR-3151 and hsa-miR-4259, 1331
of hsa-miR-611, and 1478 of hsa-miR-1236.
Conclusions
This paper presents a computational flow that helps vir-
ologists design the potential miRNA response elements
(MREs) for constructing safer live attenuated virus vac-
cines. The designed MREs of selected human miRNAs
within Influenza A H1N1 virus demonstrated the useful-
ness of the proposed computation to reduce the experi-
mental time and cost with the consistent result
comparing with previous literature. The MRE design tool
on the MicroLive web server enables users to interac-
tively find and optimize the potential MREs for a specific
human miRNA within users’ input viral sequences of
interest. The provided database allows users to explore
the miranda-predicted MREs for several RNA viruses and
try the MRE design tool based on the system-provided
sequences. While the demonstration and implementation
were based on human miRNAs and Influenza A H1N1
virus, the proposed computation could be flexibly applied
to design MREs for engineering tissue-specific oncolytic
viruses or for constructing live attenuated virus vaccines
for other hosts of interest such as animals.
Availability and requirements
• MicroLive is freely available at http://www.biotec.
or.th/isl/microlive/.
• The multiple sequence alignment of the same gene
requires Jalview java applet to display.
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Additional material
Additional file 1: List of ubiquitously expressed human miRNAs that
are conserved with mouse but not chicken.
Additional file 2: Number of compiled viral sequences in MicroLive
database.
Additional file 3: List of human MREs identified within gene
segments of Influenza A H1N1 virus with binding energy lower
than -37 KCal/Mol and having at most two amino acid substitutions
without effects on physical properties.
Additional file 4: Number of human miRNAs identified with the
miranda-predicted MREs within specific viral genes or gene
segments.
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